ZA201000151B - Pyridone gpr119 g protein-coupled receptor agonists - Google Patents
Pyridone gpr119 g protein-coupled receptor agonistsInfo
- Publication number
- ZA201000151B ZA201000151B ZA2010/00151A ZA201000151A ZA201000151B ZA 201000151 B ZA201000151 B ZA 201000151B ZA 2010/00151 A ZA2010/00151 A ZA 2010/00151A ZA 201000151 A ZA201000151 A ZA 201000151A ZA 201000151 B ZA201000151 B ZA 201000151B
- Authority
- ZA
- South Africa
- Prior art keywords
- gpr119
- pyridone
- protein
- receptor agonists
- coupled receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95016207P | 2007-07-17 | 2007-07-17 | |
| PCT/US2008/070101 WO2009012275A1 (en) | 2007-07-17 | 2008-07-16 | Pyridone gpr119 g protein-coupled receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201000151B true ZA201000151B (en) | 2011-03-30 |
Family
ID=39864683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/00151A ZA201000151B (en) | 2007-07-17 | 2010-01-08 | Pyridone gpr119 g protein-coupled receptor agonists |
| ZA2010/00326A ZA201000326B (en) | 2007-07-17 | 2010-01-15 | Methods for modulating gpr119 g protein-coupled receptor and selected compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/00326A ZA201000326B (en) | 2007-07-17 | 2010-01-15 | Methods for modulating gpr119 g protein-coupled receptor and selected compounds |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US7928230B2 (enExample) |
| EP (2) | EP2173737B1 (enExample) |
| JP (3) | JP5301539B2 (enExample) |
| KR (2) | KR20100051814A (enExample) |
| CN (3) | CN101801957A (enExample) |
| AR (2) | AR067568A1 (enExample) |
| AT (2) | ATE524460T1 (enExample) |
| AU (2) | AU2008276057B2 (enExample) |
| BR (2) | BRPI0814428A2 (enExample) |
| CA (2) | CA2693444A1 (enExample) |
| CL (2) | CL2008002111A1 (enExample) |
| CO (1) | CO6160315A2 (enExample) |
| CY (2) | CY1112151T1 (enExample) |
| DK (2) | DK2173737T3 (enExample) |
| EA (2) | EA018709B1 (enExample) |
| ES (2) | ES2371515T3 (enExample) |
| HR (2) | HRP20120221T1 (enExample) |
| IL (1) | IL228120A0 (enExample) |
| NZ (2) | NZ582661A (enExample) |
| PE (2) | PE20090449A1 (enExample) |
| PL (2) | PL2170864T3 (enExample) |
| PT (2) | PT2173737E (enExample) |
| SI (2) | SI2173737T1 (enExample) |
| TW (2) | TW200904439A (enExample) |
| WO (2) | WO2009012275A1 (enExample) |
| ZA (2) | ZA201000151B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101111480A (zh) * | 2004-12-01 | 2008-01-23 | äžæć¶èŻæ ȘćŒäŒç€Ÿ | ć代çćĄć¶é źèĄçç© |
| WO2008137435A1 (en) | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| EA018709B1 (ru) * | 2007-07-17 | 2013-10-30 | ĐŃĐžŃŃĐŸĐ»-ĐĐ°Đ”ŃŃ ĐĄĐșĐČОбб ĐĐŸĐŒĐżĐ°ĐœĐž | ĐĐžŃĐžĐŽĐŸĐœĐŸĐČŃĐ” Đ°ĐłĐŸĐœĐžŃŃŃ ŃĐŸĐżŃŃĐ¶Đ”ĐœĐœĐŸĐłĐŸ Ń g-бДлĐșĐŸĐŒ ŃĐ”ŃДпŃĐŸŃĐ° gpr119 |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | ă€ăłăżăŒăă„ăŒăłïŒ ă€ăłăłăŒăăŹă€ăăă | ççæ§ăăăłç·ç¶æ§çŸæŁăæČ»çăăăăăźććç©ăăăłæčæł |
| EP2324036B1 (en) | 2008-07-16 | 2014-12-03 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| EP2318404B1 (en) | 2008-07-16 | 2013-08-21 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| EP2408780A2 (en) * | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicycloĂœ3.3.1šnonanes |
| NZ596445A (en) | 2009-06-24 | 2013-04-26 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| MX2012011460A (es) | 2010-04-08 | 2012-11-23 | Squibb Bristol Myers Co | Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119. |
| EA201270778A1 (ru) | 2010-05-06 | 2013-04-30 | ĐŃĐžŃŃĐŸĐ»-ĐĐ°ĐčĐ”ŃŃ ĐĄĐșĐČОбб ĐĐŸĐŒĐżĐ°ĐœĐž | ĐĐžŃĐžĐșлОŃĐ”ŃĐșОД гДŃĐ”ŃĐŸĐ°ŃОлŃĐœŃĐ” Đ°ĐœĐ°Đ»ĐŸĐłĐž ĐČ ĐșĐ°ŃĐ”ŃŃĐČĐ” ĐŒĐŸĐŽŃĐ»ŃŃĐŸŃĐŸĐČ ŃĐ”ŃДпŃĐŸŃĐ° gpr119 |
| WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| DK2625177T3 (en) | 2010-10-08 | 2015-10-12 | Cadila Healthcare Ltd | New GPR 119 agonists |
| US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| WO2012078684A1 (en) | 2010-12-06 | 2012-06-14 | Confluence Life Sciences, Inc. | Substituted pyridinone-pyridinyl compounds |
| US8822471B2 (en) * | 2011-03-14 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2850073B1 (en) | 2012-05-16 | 2017-07-19 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| ES2641469T3 (es) * | 2012-11-13 | 2017-11-10 | Nissan Chemical Industries, Ltd. | Compuesto de 2-piridona |
| CN102993088A (zh) * | 2012-12-31 | 2013-03-27 | äžćć€§ćŠ | äžç§4-çŸćș-2-ćĄć¶é źçć¶ć€æčæł |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | ç¶ć代äčćć¶ććç©ćć ¶äœçșéŁæ ŸçŽ ćé«èȘżçŻćäčçšé |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | ç¶ć代ç7-æ°źééç°éĄćć ¶äœçșéŁæ ŸæżçŽ ćé«èȘżçŻćäčçšé |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | æŻć©æćć„çè„ćć Źćž | ç¶ć代ïŒïŒæ°źééç°éĄćć ¶äœçșéŁæ ŸçŽ ćé«èȘżæ§ćäčçšé |
| HUE054178T2 (hu) | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituĂĄlt piridinon-piridinil-vegyĂŒletek Ă©s fluor-pirimidinil-metoxi-szubsztituĂĄlt piridinon-piridinil-vegyĂŒletek |
| ES2761571T3 (es) | 2013-06-20 | 2020-05-20 | Bayer Cropscience Ag | Derivados de arilsulfuro y arilsulfĂłxido como acaricidas e insecticidas |
| JP2016526538A (ja) | 2013-06-20 | 2016-09-05 | ăă€ăšă«ă»ăŻăăăă”ă€ăšăłăčă»ăąăŻăă§ăłăČăŒă«ă·ăŁăă | æźșăăć€ćăłæźșè«ć€ăšăăŠăźăąăȘăŒă«ăčă«ăăŁăèȘć°äœćăłăąăȘăŒă«ăčă«ăăă·ăèȘć°äœ |
| BR112016000241B1 (pt) | 2013-07-08 | 2021-06-22 | Bayer Cropscience Aktiengesellschaft | Compostos pesticidas derivados de sulfeto de arila e sulfóxido de arila, formulação, seus usos, método para controle de pragas e método de proteção de semente ou planta |
| CN106459042B (zh) | 2014-04-02 | 2019-06-28 | è±çčç©æ©ć Źćž | æçș€ç»ŽććĄć¶é źç±» |
| EP2929883A1 (en) | 2014-04-08 | 2015-10-14 | Institut Pasteur | Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors |
| WO2016040789A1 (en) | 2014-09-11 | 2016-03-17 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
| US10399948B2 (en) | 2015-02-10 | 2019-09-03 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 3 |
| JP6578116B2 (ja) * | 2015-03-25 | 2019-09-18 | ć ŹçèČĄćŁæłäșșçžæšĄäžć€źććŠç 究æ | äžçœźæïŒăă«ăȘăăąă«ăă«ïŒăšăăŹăłéĄćăłăăźèŁœé æčæł |
| US10865194B2 (en) | 2017-11-03 | 2020-12-15 | Fondazione Istituto Italiano Di Tecnologia | Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| CN115484952B (zh) | 2020-03-27 | 2024-10-18 | éżć æçæŻæČ»çèĄä»œæéć Źćž | èą«ć代çćĄć¶é ź-ćĄć¶ćșććç©çæčæłăç»ćç©ćç»æ¶ćœąćŒ |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | ăăŁăȘăŒăȘăïŒă€ăłăŻïŒ | ïŒĄïœïœïœăąăŻăăăŒăżăŒ |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | ćĄć°äŒæźć Źćž | Ampk掻ćć |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| CN115504927A (zh) * | 2022-08-15 | 2022-12-23 | ćčżè„żäžć»èŻć€§ćŠ | 4-çČćș-2-ćŻčçČèŻćș-6-矰ćșćĄć¶-3-çČé žćć ¶ć¶ć€æčæłćçšé |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826643A (en) | 1967-08-07 | 1974-07-30 | American Cyanamid Co | Method of controlling undesirable plant species using 3-nitropyridines |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as ÎČ3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid ÎČ3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine ÎČ 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as ÎČ3 agonists |
| US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | ĐŃĐ°ĐčĐ·Đ”Ń ĐŃĐŸĐŽĐ°ĐșŃŃ ĐĐœĐș. | ЀаŃĐŒĐ°ŃĐ”ĐČŃĐžŃĐœĐ° ĐșĐŸĐŒĐżĐŸĐ·ĐžŃŃŃ, ŃĐŸ ĐŒŃŃŃĐžŃŃ ŃĐœĐłŃбŃŃĐŸŃ Đ°Đ»ŃĐŽĐŸĐ·ĐŸŃДЎŃĐșŃĐ°Đ·Đž ŃĐ° ŃĐœĐłŃбŃŃĐŸŃ ĐłĐ»ŃĐșĐŸĐłĐ”ĐœŃĐŸŃŃĐŸŃОлазО (ĐČĐ°ŃŃĐ°ĐœŃĐž), ĐșĐŸĐŒĐżĐ»Đ”ĐșŃ, ŃĐșĐžĐč ŃŃ ĐČĐșĐ»ŃŃĐ°Ń, ŃĐ° ŃĐżĐŸŃĐŸĐ±Đž Đ»ŃĐșŃĐČĐ°ĐœĐœŃ ŃŃĐ°ĐČŃŃĐČ Đ·Ń ŃŃĐ°ĐœĐŸĐŒ ŃĐœŃŃĐ»ŃĐœĐŸŃДзОŃŃĐ”ĐœŃĐœĐŸŃŃŃ |
| ATE416772T1 (de) | 1998-07-06 | 2008-12-15 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
| AU3127900A (en) | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
| WO2002002519A2 (en) | 2000-06-29 | 2002-01-10 | Bristol-Myers Squibb Pharma Company | THROMBIN OR FACTOR Xa INHIBITORS |
| DE60125227T2 (de) | 2000-12-01 | 2007-09-20 | Astellas Pharma Inc. | Verfahren zum screening von diabetes-heilverfahren |
| US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| ES2334990T3 (es) * | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | Piridinonas sustituidas como moduladores de p38 map quinasa. |
| KR101078098B1 (ko) | 2003-01-14 | 2011-10-28 | ìë ë íë§ìí°ìčŒì€, ìžíŹ. | ëìŹ ìĄ°ì ì ëĄìì ïŒ,ïŒ,ïŒ-ìŒìčíë ì늎 ë° í€í ëĄì늎ì ëìČŽ, ë° ëčëšëł ë° êł íëčìŠì ëč륯í ìŽì êŽë šëì„ì ì ìë°© ë° ìčëŁ |
| CA2515963A1 (en) | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
| SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| US7003597B2 (en) * | 2003-07-09 | 2006-02-21 | International Business Machines Corporation | Dynamic reallocation of data stored in buffers based on packet size |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| CN100509798C (zh) * | 2003-07-11 | 2009-07-08 | èŸć°Œçșłć¶èŻć Źćž | äœäžșæ°éä»Łè°ąè°èćçäžć代èłćșćæèłćșèĄçç©ä»„ćéąéČćæČ»çäžć ¶çžć łäčç ç |
| AR045697A1 (es) * | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| US20070088163A1 (en) | 2003-09-12 | 2007-04-19 | Kemia, Inc. | Modulators of calcitonin and amylin activity |
| CN1930126A (zh) * | 2004-03-05 | 2007-03-14 | äžæć¶èŻæ ȘćŒäŒç€Ÿ | ćĄć¶é źèĄçç© |
| ATE519495T1 (de) | 2004-03-17 | 2011-08-15 | 7Tm Pharma As | Y4-selektiver rezeptoragonist pp2-36 fĂŒr therapeutische eingriffe |
| DK1756096T3 (da) | 2004-05-03 | 2009-10-26 | Hoffmann La Roche | Indolylderivater som lever-X-receptormodulatorer |
| HRP20090093T3 (en) | 2004-06-04 | 2009-03-31 | Arena Pharmaceuticals Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| CA2612187C (en) | 2005-06-23 | 2013-05-07 | Emory University | Stereoselective synthesis of amino acid analogs for tumor imaging |
| JP5114395B2 (ja) * | 2005-06-30 | 2013-01-09 | ăăă·ăăŁăȘăłă»ăȘăăăă | ïœïœïœăąăŽăăčă |
| US20090221644A1 (en) | 2005-06-30 | 2009-09-03 | Stuart Edward Bradley | Gpcr Agonists |
| PE20090213A1 (es) * | 2007-05-04 | 2009-02-28 | Bristol Myers Squibb Co | Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos |
| WO2008137435A1 (en) * | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
| EA018709B1 (ru) | 2007-07-17 | 2013-10-30 | ĐŃĐžŃŃĐŸĐ»-ĐĐ°Đ”ŃŃ ĐĄĐșĐČОбб ĐĐŸĐŒĐżĐ°ĐœĐž | ĐĐžŃĐžĐŽĐŸĐœĐŸĐČŃĐ” Đ°ĐłĐŸĐœĐžŃŃŃ ŃĐŸĐżŃŃĐ¶Đ”ĐœĐœĐŸĐłĐŸ Ń g-бДлĐșĐŸĐŒ ŃĐ”ŃДпŃĐŸŃĐ° gpr119 |
-
2008
- 2008-07-16 EA EA201000210A patent/EA018709B1/ru not_active IP Right Cessation
- 2008-07-16 HR HR20120221T patent/HRP20120221T1/hr unknown
- 2008-07-16 PL PL08781867T patent/PL2170864T3/pl unknown
- 2008-07-16 US US12/173,864 patent/US7928230B2/en active Active
- 2008-07-16 NZ NZ582661A patent/NZ582661A/en not_active IP Right Cessation
- 2008-07-16 NZ NZ582664A patent/NZ582664A/en not_active IP Right Cessation
- 2008-07-16 CN CN200880108168A patent/CN101801957A/zh active Pending
- 2008-07-16 HR HR20110806T patent/HRP20110806T1/hr unknown
- 2008-07-16 AU AU2008276057A patent/AU2008276057B2/en not_active Ceased
- 2008-07-16 BR BRPI0814428-1A2A patent/BRPI0814428A2/pt not_active IP Right Cessation
- 2008-07-16 TW TW097127045A patent/TW200904439A/zh unknown
- 2008-07-16 US US12/173,856 patent/US8003796B2/en active Active
- 2008-07-16 DK DK08781868.8T patent/DK2173737T3/da active
- 2008-07-16 EA EA201000211A patent/EA016595B1/ru not_active IP Right Cessation
- 2008-07-16 AR ARP080103060A patent/AR067568A1/es unknown
- 2008-07-16 ES ES08781867T patent/ES2371515T3/es active Active
- 2008-07-16 TW TW097127046A patent/TW200904440A/zh unknown
- 2008-07-16 DK DK08781867.0T patent/DK2170864T3/da active
- 2008-07-16 WO PCT/US2008/070101 patent/WO2009012275A1/en not_active Ceased
- 2008-07-16 PT PT08781868T patent/PT2173737E/pt unknown
- 2008-07-16 KR KR1020107003333A patent/KR20100051814A/ko not_active Withdrawn
- 2008-07-16 ES ES08781868T patent/ES2378914T3/es active Active
- 2008-07-16 PE PE2008001197A patent/PE20090449A1/es not_active Application Discontinuation
- 2008-07-16 KR KR1020107003332A patent/KR20100045471A/ko not_active Withdrawn
- 2008-07-16 SI SI200830592T patent/SI2173737T1/sl unknown
- 2008-07-16 CN CN2008801081672A patent/CN101801956B/zh not_active Expired - Fee Related
- 2008-07-16 PL PL08781868T patent/PL2173737T3/pl unknown
- 2008-07-16 SI SI200830464T patent/SI2170864T1/sl unknown
- 2008-07-16 WO PCT/US2008/070103 patent/WO2009012277A1/en not_active Ceased
- 2008-07-16 PT PT08781867T patent/PT2170864E/pt unknown
- 2008-07-16 AT AT08781867T patent/ATE524460T1/de active
- 2008-07-16 AU AU2008276055A patent/AU2008276055B2/en not_active Ceased
- 2008-07-16 CA CA2693444A patent/CA2693444A1/en not_active Abandoned
- 2008-07-16 AR ARP080103061A patent/AR067569A1/es not_active Application Discontinuation
- 2008-07-16 CA CA2693439A patent/CA2693439A1/en not_active Abandoned
- 2008-07-16 EP EP08781868A patent/EP2173737B1/en not_active Not-in-force
- 2008-07-16 AT AT08781868T patent/ATE540945T1/de active
- 2008-07-16 JP JP2010517123A patent/JP5301539B2/ja not_active Expired - Fee Related
- 2008-07-16 EP EP08781867A patent/EP2170864B1/en not_active Not-in-force
- 2008-07-16 BR BRPI0815097A patent/BRPI0815097A2/pt not_active IP Right Cessation
- 2008-07-16 PE PE2008001196A patent/PE20090888A1/es not_active Application Discontinuation
- 2008-07-16 JP JP2010517122A patent/JP5318867B2/ja not_active Expired - Fee Related
- 2008-07-16 CN CN201310495045.6A patent/CN103550218A/zh active Pending
- 2008-07-17 CL CL200802111A patent/CL2008002111A1/es unknown
- 2008-07-17 CL CL200802110A patent/CL2008002110A1/es unknown
-
2010
- 2010-01-08 ZA ZA2010/00151A patent/ZA201000151B/en unknown
- 2010-01-15 ZA ZA2010/00326A patent/ZA201000326B/en unknown
- 2010-01-15 CO CO10003756A patent/CO6160315A2/es unknown
-
2011
- 2011-03-07 US US13/041,564 patent/US8178561B2/en active Active
- 2011-06-14 US US13/159,497 patent/US8232404B2/en active Active
- 2011-12-14 CY CY20111101241T patent/CY1112151T1/el unknown
-
2012
- 2012-04-09 CY CY20121100343T patent/CY1112751T1/el unknown
- 2012-04-24 US US13/454,789 patent/US20120232048A1/en not_active Abandoned
- 2012-06-12 US US13/494,489 patent/US8513424B2/en active Active
-
2013
- 2013-07-10 JP JP2013144778A patent/JP2013237680A/ja not_active Withdrawn
- 2013-08-26 IL IL228120A patent/IL228120A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201000151B (en) | Pyridone gpr119 g protein-coupled receptor agonists | |
| IL208919A0 (en) | Gpr119 receptor agonists | |
| EP2173174A4 (en) | FARNESOID X RECEPTOR AGONISTS | |
| EP2170072A4 (en) | Farnesoid X RECEPTOR AGONISTS | |
| GB0720390D0 (en) | G-Protein coupled receptor agonists | |
| GB0720389D0 (en) | G-Protein Coupled Receptor Agonists | |
| GB0607196D0 (en) | G-protein coupled receptor agonists | |
| AP2010005267A0 (en) | Novel glucocorticoid receptor agonists | |
| PL2114931T3 (pl) | Piperydynowe agonisty GPCR | |
| PL2114935T3 (pl) | Piperydynowi agoniĆci GPCR | |
| EP2041120A4 (en) | MELANOCORTIN RECEPTOR AGONISTS | |
| EP2311822A4 (en) | GPR119 AGONIST | |
| GEP20135850B (en) | Melanocortin receptor agonists | |
| PT1981902E (pt) | Antagonistas dos recetores nogo | |
| EP2474540A4 (en) | GPR119 AGONIST | |
| EP2184278A4 (en) | P2X4 RECEIVER ANTAGONIST | |
| IL198650A0 (en) | Progesterone receptor antagonists | |
| IL212545A0 (en) | Toll-like receptor 3 antagonists | |
| IL210773A0 (en) | Neuropeptide-2 receptor (y-2r) agonists and uses thereof | |
| EP2017281A4 (en) | AGONISTS AT TOLL-LIKE RECEPTOR 9 | |
| EP2153736A4 (en) | NEW LEUKOTRIEN RECEPTOR ANTAGONIST | |
| ZA201005826B (en) | Selective agonist of toll-like receptor 3 | |
| EP2222676A4 (en) | A1-adenosine receptor antagonistic | |
| EP2161994A4 (en) | UROTENSIN-II Receptor Antagonists | |
| GB0720388D0 (en) | G-protein coupled receptor agonists |